We found that tamsulosin/solifenacin therapy might increase the level of PSA in patients with PSA compared with tamsulosin monotherapy, which may increase the risk of prostate cancer (WMD = 0.192, 95% CI: 0.132 to 0.253, P < 0.001, Figure 12). This evidence concerns the gene KLK3 and prostate carcinoma.